Abstract
Tumor-induced osteomalacia, also known as oncogenic osteomalacia, is a rare paraneoplastic syndrome in which vitamin D resistant osteomalacia occurs due to the presence of a tumor. The following case report describes a young woman who seeks a second opinion from a rheumatologist and is found to have oncogenic osteomalacia. Not often discussed in the rheumatology literature, oncogenic osteomalacia is a rare and interesting disease entity in which diagnosis is often more challenging than treatment.
Similar content being viewed by others
References
Prader V, Illig R, Vehlinger E, Stalder G (1959) Rachitis, infolge, knochen tumors. Helv Paediatr Acta 14:554–565
Jonsson K, Zahradnik B, Larsson T et al (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663
Carpenter T (2003) Oncogenic osteomalacia—a complex dance of factors. N Engl J Med 348:1705–1708
Seufert J, Ebert K, Muller J et al (2001) Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345:1883–1888
Edmister KA, Sundaram M (2002) Oncogenic osteomalacia. Semin Musculoskelet Radiol 6:191–196
Nomura G, Kodshino Y, Morimoto H (1981) Vitamin D resistant hypophosphatemic osteomalacia associated with osteosarcoma of the mandible: report of a case. Jpn J Med 21:35–39
Hasegawa T, Shimoda T, Yokoyama R (1999) Intracortical osteoblastic osteosarcoma with oncogenic rickets. Skelet Radiol 28:41–45
Folpe A, Fanburg-Smith J, Billings S et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity. Am J Surg Pathol 28:1–30
Garcia C, Spencer R (2002) Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med 27:582–583
Sahin M, Basoglu T, Albayrak S (2001) Pentavalent technetium-99m DMSA uptake in pseudofractures of osteomalacia. Clin Nucl Med 26:62
Jan de Beur SM (2005) Tumor induced osteomalacia. JAMA 94:1260–1267
Shimada T, Mizutani S, Muto T et al (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505
Yamashita T, Konsishi M, Miayke A et al (2002) Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of themitogen-activated protein kinase pathway. J Biol Chem 277:28265–28270
Shimada T, Muto T, Urakawa I et al (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182
Nelson A, Bligh R, Mirams M et al (2003) Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab 88:4088–4094
Takeuchi Y, Suzuki H, Ogura S et al (2004) Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89:3979–3982
Schapira D, Izhak O, Nachtigal A et al (1995) Tumor induced osteomalacia. Semin Arthritis Rheum 25:35–46
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kaul, M., Silverberg, M., DiCarlo, E.F. et al. Tumor-induced osteomalacia. Clin Rheumatol 26, 1575–1579 (2007). https://doi.org/10.1007/s10067-006-0468-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0468-y